Abstract:AbstractBackgroundVarious treatments to improve live birth rate in women suffering unexplained recurrent pregnancy loss (URPL) have proven ineffective. Cyclosporin A (CsA), an immunosuppressant widely used in organ transplantation, can induce maternal–foetal immune tolerance and improve trophoblast cell biological function. Whether CsA administration in the first trimester increases live birth rate in URPL women remains unknown.MethodsA single‐centre, prospective, observational cohort study of URPL patients treated at Obstetrics and Gynecology Hospital of Fudan University was conducted between 2010 and 2016. Participants within 6 weeks of gestation were divided into two groups: CsA or dydrogesterone. To compare efficacy and safety of interventions, data describing maternal and foetal conditions throughout 180 days after labour were collected. Mathematical models were used to identify the miscarriage risk factors in the subsequent pregnancy.Findings908 of 1931 women aged 18–40 with naturally conceived children and URPL history were recruited and received CsA (n = 660) or dydrogesterone (n = 248) treatment. The live birth rates in CsA and dydrogesterone groups were 88.31% and 89.36%, respectively (relative risk 0.99; 95% confidence interval 0.94–1.04; p = .72). Except for ectopic pregnancy only in dydrogesterone group (p = .005), there was no significant difference in outcomes of miscarriage, preterm birth, full‐term birth, stillbirth or continued pregnancy. There was no discernible difference between CsA and dydrogesterone groups regarding maternal complications, congenital foetal abnormalities and growth. Potential risk factors for miscarriage in URPL patients included maternal age, number of prior pregnancies and miscarriages, the levels of serum progesterone, regulatory T‐cell (Tregs, CD4+CD25+CD127−T), blocking antibody and anti‐idiotypic antibody.InterpretationIn women with URPL, short‐term CsA therapy during the first trimester may increase the likelihood of live birth. The effectiveness of CsA is comparable to dydrogesterone without increasing risk of maternal complications or foetus congenital abnormalities. For women experienced URPL, CsA may be a potential therapeutic medicine.

Effects of Cyclosporin A on the Peripheral CD4+CD25+T Cells and the Outcomes of Gestation in Abortion-Prone Matings

Cyclosporine A inducing expansion of the CD4+CD25+Foxp3+ regulatory T cells and peripheral materno-fetal immune tolerance in abortion-prone matings

Cyclosporin A improves murine pregnancy outcome in abortion-prone matings: involvement of CD80/86 and CD28/CTLA-4.

Cyclosporin a improves pregnancy outcome by promoting functions of trophoblasts and inducing maternal tolerance to the allogeneic fetus in abortion-prone matings in the mouse.

Cyclosporin A Modulates the Secretion of IL-10 and IFN-γ by Human Decidual Immuno-Competent Cells

The Regulation of Cyclosporin A on the Ratio of IL-10 to IFN-γ at Human Maternal-Fetal Interface

The Favorable Modulation of Cyclosporin A on the Biological Behaviors of Trophoblast Cells

Study on role of paternal antigens-specific CD4+CD25+T regulatory cells during pregnancy

Astilbin Improves Pregnancy Outcome in Rats with Recurrent Spontaneous Abortion by Regulating Th1/Th2 Balance.

Immunosurgical studies on cytological and cytogenetic toxicity analysis of rat blastocysts after in vivo exposure to cyclophosphamide

Inducing Peripheral Materno-Fetal Immuno-Tolerance by Blockade of Costimulatory Signal at Early Stage of Gestation of the Abortion-Prone Murine Model

Cyclosporine A Improves Adhesion and Invasion of Mouse Preimplantation Embryos Via Upregulating Integrin Β3 and Matrix Metalloproteinase-9.

Impacts of Cyclosporin A on Clinical Pregnancy Outcomes of Patients with a History of Unexplained Transfer Failure: a Retrospective Cohort Study

Effects of cyclophosphamide on protein expression of rat embryo at end of pre-gastrulation stage in vivo.

Blockade of CD86 signaling facilitates a Th2 bias at the maternal-fetal interface and expands peripheral CD4+CD25+ regulatory T cells to rescue abortion-prone fetuses.

Blockade of CD86 Signaling Facilitates a Th2 Bias at the Maternal-Fetal Interface and Expands Peripheral CD4+CD25+ Regulatory T Cells to Rescue Abortion-Prone Fetuses1

Short‐term Cyclosporin A Treatment Improves Pregnancy Outcomes in Patients with Unexplained Pregnancy Loss: A Prospective, Open‐label, Observational Study

Blockade of CD80 and CD86 at the Time of Implantation Inhibits Maternal Rejection to the Allogeneic Fetus in Abortion-Prone Matings

Effect of Adoptive Transfer of Embryo Antigen-Tolerant T Cells on the Expression of Cytokines at Materno-Fetal Interface of the Recipient Mice

Adoptive transfer of T cells from the normal pregnancy mice suppresses maternal rejection to the allogeneic fetus in the abortion-prone mice

Effects of cyclosporine A on proliferation, invasion and migration of HTR-8/SVneo human extravillous trophoblasts